Review of Financial Studies Vol. 38 No. 9 2025
Competition and Innovation Revisited: A Project-Level View
Abstract
We offer new evidence on the relationship between competition and innovation that overcomes two measurement difficulties compromising the extant literature: aggregation at either firm level (or higher) of innovative activity, and the mediating influence of distance-to-technological-frontier. FDA awards of Breakthrough Therapy Designations (BTDs) on specific drugs, instrument stochastic unleveling of therapeutic (ie, product) markets. Rivals’ innovative responses generally show an inverted-U pattern in ex ante competitiveness of the shocked market. However, the shape of the relation changes with distance to technological frontier in that market, proxied by whether the rival project uses one of the technologies embedded in the BTD-awarded drug.
- DOI
- 10.1093/rfs/hhae078
- Volume
- 38
- Issue
- 9
- Pages
- 2652-2717
- Language
- en
- Sources
- bibtex:phds-export.bib openalex crossref